Presented by Dr Filip Van Herpe (University Hospitals Leuven, Belgium)
In this video, Dr Filip Van Herpe, digestive oncologist at the University Hospitals Leuven, summarizes the key takeaways from the proffered paper session on lower digestive tract cancers at ESMO 2025.
One of the most notable updates during the session came from the MATTERHORN trial, a large global phase III study testing durvalumab in combination with perioperative FLOT chemotherapy in patients with gastric or gastroesophageal junction adenocarcinoma. The results demonstrated a significant improvement in overall survival (HR [95% CI]: 0.78 [0.63–0.96], p = 0.021), building on the previously positive findings for event-free survival. Importantly, pathological complete response and major pathological response were shown to be prognostic indicators, underscoring their value as potential surrogate endpoints in future studies.¹ These findings reinforce the role of immunotherapy in the perioperative setting and suggest that durvalumab combined with FLOT may represent a new standard across diverse patient populations, including both Asian and Western cohorts.
The potential of adjuvant immunotherapy in esophageal squamous cell carcinoma was explored in the SKYSCRAPER-07 trial.² In this trial, maintenance therapy with atezolizumab alone, or in combination with the anti-TIGIT antibody tiragolumab, was evaluated after definitive chemoradiation. While the dual immunotherapy arm did not meet its primary endpoints, exploratory analysis of atezolizumab monotherapy revealed a signal of benefit compared with placebo. This suggests that single-agent PD-L1 inhibition may still be valuable in the adjuvant setting. These results reflect both the promise and the complexity of refining immunotherapy strategies in esophageal cancer, where the balance between efficacy and tolerability is critical.
Efforts to combine tyrosine kinase inhibitors with immune checkpoint inhibitors were less encouraging. In fact, two trials pairing regorafenib or lenvatinib with PD-1 or PD-L1 antibodies failed to demonstrate improved outcomes in either squamous carcinoma or gastroesophageal adenocarcinoma. ³ ,⁴ These findings add to a growing consensus that such combinations, despite theoretical synergy, do not deliver meaningful benefit in upper GI malignancies and are unlikely to alter clinical practice.
Finally, a Chinese phase III trial (KC-WISE) evaluated a bispecific antibody targeting HER2 (anbenitamab), administered with chemotherapy, in patients who had progressed after platinum-based therapy and trastuzumab. Both progression-free and overall survival were significantly longer with this combination compared to chemotherapy alone, confirming the activity of this novel agent.⁵ However, with trastuzumab deruxtecan established as the standard in the second-line setting, the potential place for this new therapy in the treatment algorithm remains uncertain. Without clear data on sequencing relative to trastuzumab deruxtecan, it is difficult to assess the true clinical impact of anbanitamab, and further studies will be necessary to clarify its role.
References:
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in
Donderdag 12 november 2026
Kontich
Gent
Linter
Onthaal vanaf 18 uur
Programma van 19 tot 22 uur
Kies jouw locatie en schrijf je in